抄録
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. Primary objective. To assess the effects of skincare interventions, such as emollients, for prevention of eczema and food allergy in infants. Secondary objectives. To ascertain whether active skincare interventions, commenced in early infancy, influence risk of developing eczema or food allergy To identify features of the study populations such as age, hereditary risk and adherence to the interventions, which are associated with the greatest treatment benefit or harm for both eczema and food allergy.
| 本文言語 | English |
|---|---|
| 論文番号 | CD013534 |
| ジャーナル | Cochrane Database of Systematic Reviews |
| 巻 | 2020 |
| 号 | 2 |
| DOI | |
| 出版ステータス | Published - 2020 2 10 |
ASJC Scopus subject areas
- Pharmacology (medical)
フィンガープリント 「Skincare interventions in infants for preventing eczema and food allergy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Skincare interventions in infants for preventing eczema and food allergy. / Kelleher, Maeve M.; Cro, Suzie; Cornelius, Victoria; Axon, Emma; Lodrup Carlsen, Karin C.; Skjerven, Håvard Ove; Rehbinder, Eva Maria; Lowe, Adrian; Dissanayake, Eishika; Shimojo, Naoki; Yonezawa, Kaori; Ohya, Yukihiro; Yamamoto-Hanada, Kiwako; Morita, Kumiko; Surber, Christian; Cork, Michael; Cooke, Alison; Tran, Lien; Askie, Lisa M.; Duley, Lelia; Chalmers, Joanne R.; Williams, Hywel C.; Boyle, Robert J.
In: Cochrane Database of Systematic Reviews, Vol. 2020, No. 2, CD013534, 10.02.2020.研究成果: Article › 査読
}
TY - JOUR
T1 - Skincare interventions in infants for preventing eczema and food allergy
AU - Kelleher, Maeve M.
AU - Cro, Suzie
AU - Cornelius, Victoria
AU - Axon, Emma
AU - Lodrup Carlsen, Karin C.
AU - Skjerven, Håvard Ove
AU - Rehbinder, Eva Maria
AU - Lowe, Adrian
AU - Dissanayake, Eishika
AU - Shimojo, Naoki
AU - Yonezawa, Kaori
AU - Ohya, Yukihiro
AU - Yamamoto-Hanada, Kiwako
AU - Morita, Kumiko
AU - Surber, Christian
AU - Cork, Michael
AU - Cooke, Alison
AU - Tran, Lien
AU - Askie, Lisa M.
AU - Duley, Lelia
AU - Chalmers, Joanne R.
AU - Williams, Hywel C.
AU - Boyle, Robert J.
N1 - Funding Information: This systematic review is supported by the award of an NIHR Transitional Research Fellowship to MK hosted by Imperial College London, and the award of an NIHR Research for Patient Benefit grant to Nottingham University Hospitals NHS Trust. Funding Information: This publication presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Funding Information: The NIHR also supported this project via Cochrane Infrastructure funding to Cochrane Skin. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. Funding Information: Maeve Kelleher: I have received honoraria for speaking at educational conferences organised by Nutricia, which does not manufacture/ market any of the interventions or potential comparators in this review. Suzie Cro: none known. Victoria Cornelius: none known EmmaAxon: none known Karin C Lodrup Carlsen: my institution received money from multiple sources: The Regional Health Board South East, the Norwegian Research Council, Oslo University Hospital, the University of Oslo, Health and Rehabilitation Norway, Østfold Hospital Trust, Norwegian Association of Asthma and Allergy, the Kloster Foundation, Norwegian society of Dermatology and Venerology, Arne Ingel's scholarship, First Medical Laboratory, the Foundation for Healthcare and Allergy Research in Sweden, the Vårdal Foundation, Swedish Asthma and Allergy Association's Research Foundation, Swedish Research Council, the Initiative for Clinical Therapy Research, the Swedish Heart-Lung Foundation, SFO-V Karolinska Institutet, Hesselman Research Foundation, and Thermo-Fisher, Uppsala, Sweden. My institution received an honorarium and travel expenses from Thermo Fischer, Uppsala, Sweden for a lecture at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018. Håvard Ove Skjerven: My institution received money for the PreventADALL study (Lødrup 2018) from the two largest governmental grant agencies in Norway, The South-Eastern Norway Regional Health Authority and the Norwegian Research Council, which are not commercial sponsors. Eva Maria Rehbinder declares no real or perceived conflict of interest for the present review, however I have received honoraria for presentations on atopic dermatitis and psoriasis from Sanofi Genzyme, Perrigo, MEDA, Novartis and Norwegian patient organizations for atopic dermatitis and psoriasis in the last 36 months. Adrian Lowe: has received grant funding from the National Health and Medical Research Council to undertake a skin barrier intervention study. He also declares that Primus Pharmaceuticals have donated EpiCeram (a skin barrier treatment) for the use in these studies, free of charge. Eishika Dissanayake: none known Naoki Shimojo: none known Kaori Yonezawa: My institution has received grants from the Mitsubishi Foundation and Mishima Kaiun Memorial Foundation that supported the research of this review. Also from Hoyu Science Foundation and JSPS KAKENHI Grant Number 17K17676 for other research. Yukihiro Ohya: I received honorarium for lectures from Abbvie, Kao, Kyorin Pharmaceutical, Maruho, Mylan, Natural science, Sanofi, Taiho Pharma and Torii pharmaceutical, and payment for consultancy for opening a forum from Maruho. Kiwako Yamamoto-Hanada: I have received payment for lectures from Sato Pharmaceutical and travel expenses from Thermo Fisher Scientific. Kumiko Morita: outside this work, I have received speakers' honoraria from Maruho Japan and Astellas Pharma, Japan. Christian Surber has received money for consultancy, lectures and development of educational presentations from LEO Pharma (Switzerland, Germany & Denmark), explaining galenical concepts including supersaturation; and for lectures and development of educational presentations for explaining galenical concepts including nano emulsions, from Almirall, Germany. Michael Cork: His institution has received fees, grants, support for travel to meetings, consultancy, or honorarium from Hyphens Pharma, L'Oreal (La Roche Possay), and Johnson & Johnson. His institution has received grants or has grants pending from Regeneron in Collaboration with Sanofi-Genzyme, Pfizer, Galapagos, and Kymab. His institution has received payment for development of educational presentations from Regeneron in Collaboration with Sanofi-Genzyme. He has been a paid consultant for or received payment for lectures or travel, accommodation, or meeting expenses from Regeneron in Collaboration with Sanofi-Genzyme, Pfizer, Galapagos, and Kymab. He is/has been a paid consultant for Hyphens Pharma, L'Oreal (La Roche Possay), and Johnson & Johnson and has also received fees and support for travel to meetings from these organisations. Alison Cooke: was funded by a National Institute for Health Research Doctoral Research Fellowship for the OBSeRvE (Oil in Baby Skincare) study. This work was independent research supported by the National Institute for Health Research (Doctoral Research Fellowship DRF-2012-05-160). She was an invited expert to an advisory panel on infant skin care; her consultancy fee from Johnson and Johnson was paid to her institution. She was an invited expert speaker at a neonatal skin care symposium at the Royal College of Midwives Annual Conference and at the European Midwives Association Conference, for which she received support from Johnson and Johnson. Lien Tran: none known Lisa M Askie: none known Lelia Duley: none known Joanne R Chalmers: my institution received money from NIHR for a Research for patient benefit grant on which I am a co-applicant. I am co-applicant on the BEEP trial and the BEEP pilot trial, both of which are likely to be included in this review (Chalmers 2017). Hywel C Williams: I am director of the NIHR HTA Programme. HTA is part of the NIHR which also supports the NIHR systematic reviews programme from which this work is funded I am chief investigator of the BEEP study which will be included in this review. Funds go to my University (Nottingham) from the National Institute for Health Research (public funds) as a result of open competition. Robert J Boyle has received payment for participating in advisory boards for DBV technologies, Prota therapeutics and ALK-Abello, who develop allergy diagnostics or treatments; has received payment for designing a clinical trial for Dairy Goat Co-operative; and has received payment for providing expert testimony in a class action related to an infant formula health claim. Funding Information: MK is supported by a Transitional Research Fellowship. This funding provides for her Nottingham and Imperial College London) and statistical support from authors EA and VC The National Institute for Health Research (NIHR), UK.
PY - 2020/2/10
Y1 - 2020/2/10
N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. Primary objective. To assess the effects of skincare interventions, such as emollients, for prevention of eczema and food allergy in infants. Secondary objectives. To ascertain whether active skincare interventions, commenced in early infancy, influence risk of developing eczema or food allergy To identify features of the study populations such as age, hereditary risk and adherence to the interventions, which are associated with the greatest treatment benefit or harm for both eczema and food allergy.
AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. Primary objective. To assess the effects of skincare interventions, such as emollients, for prevention of eczema and food allergy in infants. Secondary objectives. To ascertain whether active skincare interventions, commenced in early infancy, influence risk of developing eczema or food allergy To identify features of the study populations such as age, hereditary risk and adherence to the interventions, which are associated with the greatest treatment benefit or harm for both eczema and food allergy.
UR - http://www.scopus.com/inward/record.url?scp=85079491840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079491840&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD013534
DO - 10.1002/14651858.CD013534
M3 - Article
AN - SCOPUS:85079491840
VL - 2020
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
SN - 1361-6137
IS - 2
M1 - CD013534
ER -